Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
Crossref DOI link: https://doi.org/10.1186/s12883-016-0635-y
Published Online: 2016-07-26
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gold, Ralf
Radue, Ernst-Wilhelm
Giovannoni, Gavin
Selmaj, Krzysztof
Havrdova, Eva
Stefoski, Dusan
Sprenger, Till
Montalban, Xavier
Cohan, Stanley
Umans, Kimberly
Greenberg, Steven J.
Ozen, Gulden
Elkins, Jacob
Funding for this research was provided by:
Biogen
AbbVie